Progyny, Inc. (NASDAQ:PGNY) Stock Holdings Lessened by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. cut its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 51.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,000 shares of the company's stock after selling 87,500 shares during the quarter. Tocqueville Asset Management L.P. owned 0.10% of Progyny worth $1,449,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in PGNY. Leibman Financial Services Inc. boosted its holdings in shares of Progyny by 100.7% in the 4th quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company's stock valued at $1,096,000 after buying an additional 31,872 shares during the period. Fort Washington Investment Advisors Inc. OH lifted its holdings in Progyny by 90.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after acquiring an additional 695,740 shares during the last quarter. Aurora Investment Counsel acquired a new position in Progyny in the third quarter valued at approximately $1,280,000. Clear Harbor Asset Management LLC bought a new position in shares of Progyny during the fourth quarter valued at approximately $989,000. Finally, Barclays PLC lifted its holdings in shares of Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company's stock worth $11,835,000 after purchasing an additional 594,140 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PGNY. Canaccord Genuity Group upped their price objective on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday, February 28th. JPMorgan Chase & Co. upped their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Finally, Bank of America lifted their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Progyny currently has a consensus rating of "Hold" and an average target price of $24.82.

Remove Ads

Insider Activity at Progyny

In other news, Chairman David J. Schlanger bought 150,000 shares of the business's stock in a transaction on Thursday, December 26th. The shares were bought at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the purchase, the chairman now directly owns 228,269 shares in the company, valued at $3,350,988.92. This trade represents a 191.65 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.30% of the stock is owned by insiders.

Progyny Trading Up 0.9 %

PGNY stock traded up $0.19 during mid-day trading on Monday, reaching $22.05. 1,493,260 shares of the stock traded hands, compared to its average volume of 1,615,687. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $38.98. The stock's fifty day moving average is $21.93 and its 200-day moving average is $18.55. The company has a market cap of $1.88 billion, a P/E ratio of 38.02, a P/E/G ratio of 2.39 and a beta of 1.41.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.